Response to Comments on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites"
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs.
Nwabufo C, Bendayan R Trends Pharmacol Sci. 2022; 43(12):1041-1054.
PMID: 36374805 PMC: 9510059. DOI: 10.1016/j.tips.2022.09.005.
References
1.
Eckle T, Koeppen M, Eltzschig H
. Role of extracellular adenosine in acute lung injury. Physiology (Bethesda). 2009; 24:298-306.
DOI: 10.1152/physiol.00022.2009.
View
2.
Panigrahi R, Chandra P, Ferraris P, Kurt R, Song K, Garry R
. Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1. J Virol. 2014; 89(1):626-42.
PMC: 4301154.
DOI: 10.1128/JVI.02492-14.
View
3.
Morote-Garcia J, Kohler D, Roth J, Mirakaj V, Eldh T, Eltzschig H
. Repression of the equilibrative nucleoside transporters dampens inflammatory lung injury. Am J Respir Cell Mol Biol. 2013; 49(2):296-305.
PMC: 5455298.
DOI: 10.1165/rcmb.2012-0457OC.
View
4.
Taniguchi-Ponciano K, Vadillo E, Mayani H, Gonzalez-Bonilla C, Torres J, Majluf A
. Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. Ann Med. 2020; 53(1):197-207.
PMC: 7784832.
DOI: 10.1080/07853890.2020.1858234.
View
5.
Miller S, McGrath M, Zorn K, Ekins S, Wright S, Cherrington N
. Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. Mol Pharmacol. 2021; 100(6):548-557.
PMC: 8626781.
DOI: 10.1124/molpharm.121.000333.
View